Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: study protocol for a pilot randomized controlled trial, the PROTECTION trial
Tommaso Mauri,
Giuseppe Foti,
Carla Fornari,
Jean-Michel Constantin,
Claude Guerin,
Paolo Pelosi,
Marco Ranieri,
Sara Conti,
Daniela Tubiolo,
Egle Rondelli,
Federica Lovisari,
Tommaso Fossali,
Savino Spadaro,
Domenico Luca Grieco,
Paolo Navalesi,
Italo Calamai,
Tobias Becher,
Oriol Roca,
Yu-Mei Wang,
Rihard Knafelj,
Andrea Cortegiani,
Jordi Mancebo,
Laurent Brochard,
Antonio Pesenti,
for the Protection Study Group
Affiliations
Tommaso Mauri
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan
Giuseppe Foti
ASST Monza, University of Milan-Bicocca
Carla Fornari
Research Centre on Public Health, School of Medicine and Surgery, University of Milan-Bicocca
Jean-Michel Constantin
Department of Preoperative Medicine, University Hospital of Clermont-Ferrand
Claude Guerin
Service de Réanimation Médicale, Hôpital de la Croix Rousse
Paolo Pelosi
Department of Surgical and Integrated Diagnostics, San Martino Policlinico Hospital, IRCCS for Oncology, University of Genoa
Marco Ranieri
Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome
Sara Conti
Research Centre on Public Health, School of Medicine and Surgery, University of Milan-Bicocca
Daniela Tubiolo
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan
Egle Rondelli
ASST Monza, University of Milan-Bicocca
Federica Lovisari
Department of Anesthesia and Critical Care, Niguarda Hospital, University of Milan-Bicocca
Tommaso Fossali
Department of Anesthesiology and Intensive Care, ASST Fatebenefratelli Sacco - Luigi Sacco Hospital
Savino Spadaro
Department of morphology, surgery and experimental medicine, Azienda Ospedaliera-Universitaria Arcispedale Sant’Anna
Domenico Luca Grieco
Department of Anesthesiology and Intensive Care Medicine, Catholic University of The Sacred Heart, IRCCS Fondazione Policlinico A. Gemelli
Paolo Navalesi
Dipartimento di Scienze Mediche e Chirurgiche, Università Magna Graecia di Catanzaro, Azienda Ospedaliera Universitaria Mater Domini
Italo Calamai
AUSL Toscana Centro, Unit of Anesthesia and Resuscitation, San Giuseppe Hospital
Tobias Becher
Department of Anesthesiology and Intensive Care Medicine, University Medical Center Schleswig-Holstein
Oriol Roca
Critical Care Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona
Yu-Mei Wang
Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University
Rihard Knafelj
Center for Internal Intensive medicine (MICU), University Medical Center Ljubljana
Andrea Cortegiani
Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo
Jordi Mancebo
Servei de Medicina Intensiva, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB)
Laurent Brochard
Interdepartmental Division of Critical Care Medicine, University of Toronto
Antonio Pesenti
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan
Abstract Background Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment, decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF). These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury, shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding sigh to PSV (the PROTECTION study). Methods PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units (ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and undergoing PSV from 4 to 24 h will be enrolled. All patients will first undergo a 30-min sigh test by adding sigh to clinical PSV for 30 min to identify early oxygenation responders. Then, patients will be randomized to PSV or PSV + sigh until extubation, ICU discharge, death or day 28. Sigh will be delivered as a 3-s pressure control breath delivered once per minute at 30 cmH2O. Standardized protocols will guide ventilation settings, switch back to controlled ventilation, use of rescue treatments, performance of spontaneous breathing trial, extubation and reintubation. The primary endpoint of the study will be to verify the feasibility of PSV + sigh evaluated through reduction of failure to remain on assisted ventilation during the first 28 days in the PSV + sigh group versus standard PSV (15 vs. 22%). Failure will be defined by switch back to controlled ventilation for more than 24 h or use of rescue treatments or reintubation within 48 h from elective extubation. Setting the power to 80% and first-risk order to 5%, the computed size of the trial is 129 patients per arm. Discussion PROTECTION is a pilot randomized controlled trial testing the feasibility of adding sigh to PSV. If positive, it will provide physicians with an effective addition to standard PSV for lung protection, able to reduce failure of assisted ventilation. PROTECTION will provide the basis for a future larger trial aimed at verifying the impact of PSV + sigh on 28-day survival and ventilator-free days. Trial registration ClinicalTrials.gov, NCT03201263. Registered on 28 June 2017.